Table 3. Resistance profiling of gram-positive bacteria identified from UTI patients.
| Antimicrobial tested | Number of Isolates n = 63, | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Classes | Antibiotics | S.aureus (n = 10) | CoNS (n = 33) | Enterococcus spp (n = 16) | S.agalactiae (n = 4) | Total | ||||
| Total | R (%) | Total | R (%) | Total | R (%) | Total | R (%) | R (%) | ||
| Nitrofurantoin | FM | 6 | 0 | 17 | 4(23.5) | 5 | 3(60) | 3 | 0 | 7(29) |
| Aminoglycosides | GEM | 9 | 4(44.4) | 21 | 5(24) | - | - | 3 | 1(33.3) | 10(30.3) |
| Glycopeptide | VAN | - | - | - | - | 2 | 1(50) | 4 | 2(50) | 3(50) |
| Penicillin | OX | 4 | 4(100) | 18 | 6(31.6) | - | - | 3 | 2(66.7) | 12(48) |
| PEN | 3 | 3(100) | 10 | 9(90) | 4 | 2(50) | 4 | 3(75) | 17(66.7) | |
| Quinolones | CIP | 6 | 5(83.3) | 23 | 17(74) | 14 | 10(71.4) | 3 | 2(66.7) | 34(74) |
| NOR | 7 | 7(100) | 9 | 7(77.8) | 8 | 4(50) | 4 | 3(75) | 21(75) | |
| Lincosamides | CLN | 5 | 2(40) | 11 | 1(9.1) | - | - | - | - | 3(18.8) |
| Macrolides | ERY | 6 | 4(66.7) | 11 | 7(63.6) | 4 | 2(50) | 3 | 2(66.7) | 15(62.5) |
| Sulfonamides | SXT | 10 | 8(80) | 24 | 17(71) | - | - | - | - | 25(73.5) |
| Tetracycline | TE | 4 | 4(100) | 12 | 5(41.7) | 12 | 9(75) | 4 | 3(75) | 21(65.6) |
| Overall AMR for a bacterium | 60 | 41(68.3) | 156 | 79(50.6) | 49 | 31(63.3) | 31 | 18(58) | (51%) | |
| Overall AMR for isolates | Total tested isolates 337 Resistance isolates 169 (51%) | |||||||||
Key: Ciprofloxacin (CIP), Clindamycin (CLN), Nitrofurantoin (FM), Trimethoprim-sulphametazol (SXT), Norfloxacin (Nor), Tetracycline (TE), Oxacillin (OX), Erythromycin (ERY), Penicillin (PEN), Vancomycin (VAN) and Gentamycin (GEN), Total = Total number of tested isolates, R = resistance isolates in percentage, AMR = Antimicrobial resistance.